TCM
TNXP icon

Tang Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Tang Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55
Closed -$650K – 112
2023
Q1 		$650K Sell
55
-170
-76% -$2.92M 0.1% 84
2022
Q4 		$1.75M Buy
+225
New +$1.94M 0.25% 64

Other funds holding TNXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Tang Capital Management's TNXP Position: Q2 2023 in Review

Tang Capital Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2023, closing a stake of 55 shares — an estimated $650K sold.

Tang Capital Management first reported a position in TNXP in Q4 2022 and held it in 2 quarters. The position peaked at $1.75M in Q4 2022. 14 funds tracked by Wall St. Rank hold TNXP as of Q2 2023.

  • Tang Capital Management reported no remaining Tonix Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Tang Capital Management sold 55 Tonix Pharmaceuticals shares in Q2 2023, an estimated $650K.
  • Tang Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Tang Capital Management's Tonix Pharmaceuticals position peaked at $1.75M in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2023.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.